Hubert H. Fernandez, MD, FAAN
Professor of Medicine (Neurology)
Cleveland Clinic Lerner College of Medicine
Head, Section of Movement Disorders
Center for Neurological Restoration
Cleveland Clinic, Neurological Institute
Cheryl H. Waters, MD, FRCPC
Albert B. and Judith L. Glickman Professor
Division of Movement Disorders
New York, NY
Physicians: 1 Credit Hour
Nurses: 1 Contact Hour Medium
THIS PROGRAM WAS FIRST PRESENTED AS 7 LIVE WEBCONFERENCE SESSION STARTING JUNE 11, 2012. IF YOU HAVE ALREADY RECEIVED CREDIT DURING ONE OF THE LIVE WEBCONFERENCE SESSIONS YOU ARE INELIGIBLE TO RECEIVE CREDIT FOR THIS ENDURING ACTIVITY.
An estimated 1 million adults in the United States have Parkinsonís disease (PD). Neurologists and other clinicians specializing in movement disorders play a vital role in improving outcomes for patients with PD. However, much uncertainty about optimal treatment approaches and variability in clinical practice remains.
Wide variability in clinical practice points to an opportunity for clinicians to improve competency in providing the highest quality of care according to treatment guidelines and the latest clinical evidence. Clinicians managing patients with PD need to be familiar with current evidence regarding new therapies and strategic approaches available for the treatment of the different stages of PD. The goal of this continuing medical education activity is to improve competency and build additional skills among neurologists and other clinicians regarding best practices in the diagnosis and treatment of PD, ultimately improving outcomes for patients with PD.
METHOD OF PARTICIPATION: Participants will listen and view a pre-recorded audio presentation and question and answer session. Program Developer/Facilitator
Jointly Provided by AKH Inc. and MCM Education Target Audience
This program has been developed for movement disorder specialists, general neurologists, gerontologists, advanced practice nurses, nurse practitioners, and other healthcare clinicians involved in the care of patients with Parkinsonís disease.
Upon completion of this educational activity, the participant should be able to:
Identify early features of Parkinsonís disease (PD) to expedite diagnosis of PD.
Develop customized treatment plans for PD patients based on unique phases and clinical manifestations of PD.
Discuss the clinical differences between MAO-B inhibitors and other classes of pharmaceutical agents that may impact therapeutic decisions for individual patients.
Review ongoing trials for PD and their potential to improve motor function, mental health, and cognition in patients with PD.
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity. AKH and MCM Education planners and reviewers have no relevant financial relationships to disclose.
Dr. Fernandez discloses that he has received research support from Abbott Laboratories, Inc.; ACADIA Pharmaceuticals Inc.; Biotie Therapies; EMD Serono, Inc.; IPSEN; Merz Pharma; Novartis Pharmaceuticals; Teva Pharmaceuticals; Schering-Plough Corporation, and Synosia Therapeutics (Acquired by Biotie Therapies in 2011); honoraria from Allergan, Inc.; IPSEN; Merz Pharma; Teva Neuroscience, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd.; US WorldMeds; and is a consultant/steering committee member with Abbott Laboratories, Inc., EMD Serono, IPSEN; Merz Pharma; and United BioSource Corporation.
Dr. Waters discloses that she has received honoraria from Teva Pharmaceuticals; and has received research funding from Abbott Laboratories, Inc.; Schering-Plough Corporation; and Synosia Therapeutics (Acquired by Biotie Therapies in 2011).
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
Physician Continuing Medical Education: This educational activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and MCM Education. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Continuing Education: AKH Inc. is accredited as a provider of continuing nursing education by the American Nurses Credentialing Centerís COA.
AKH Inc. designates this educational activity for 1 contact hour (0.1 CEU). Accreditation applies solely to educational activities and does not imply approval or endorsement of any commercial product by the ANCC-COA.
Participants must view/listen to the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing education credit. Credit will be awarded for a score of 70% or better, and a statement may be printed immediately after passing the post-test online.
Commercial Support Statements
Supported by an educational grant from Teva Neuroscience, Inc., a subsidiary of Teva Pharmaceutical Industries Ltd.